Teverelix LA: Phase IIa start

Ardana began a placebo-controlled European Phase IIa trial in 70 patients. Ardana acquired rights to Teverelix from Zentaris, a wholly owned subsidiary of Aeterna Laboratories Inc. (TSE:AEL; AELA, Qu...